Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.44 |
| ▸ | HMGCR | P04035 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9309385 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL1696132 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL9697065 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL18911586 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL15416 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL120107 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL44157 | 1.00 | — | — | |
| SCHEMBL74679 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL4874844 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL17090795 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. DELAWARE | 2008-02-21 | — | — | US | claimed |
| WO-2007117581-A2 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20070116757-A1 | Methylene Blue Derivatives | COLLEGIUM PHARMACEUTICAL, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007056439-A1 | SALTS OF METHYLENE BLUE AND ITS DERIVATIVES | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| WO-1999010359-A2 | LIPOSOMIC BASED SIALYL LEWIS X MIMETICS | NOVARTIS AG (CH) | 1999-03-04 | — | — | WO | claimed |
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | claimed |
| US-3991045-A | ANTICARCINOGENIC AND ANTITUMOR AGENT, INSECTICIDES, FUNGICIDAL SURFACTANT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1976-11-09 | — | — | US | claimed |
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | NIPPON SHOKUBAI CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| WO-2023238837-A1 | EXOSOME COMPLEX AND MANUFACTURING METHOD THEREOF | JSR株式会社 | 2023-12-14 | — | — | WO | disclosed |
| US-10745669-B2 | Culture method for stable proliferation of pluripotent stem cell while maintaining undifferentiated state | AJINOMOTO CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| US-10662411-B2 | Culture method for stable proliferation of pluripotent stem cell while maintaining undifferentiated state | AJINOMOTO CO., INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20190136202-A1 | CULTURE METHOD FOR STABLE PROLIFERATION OF PLURIPOTENT STEM CELL WHILE MAINTAINING UNDIFFERENTIATED STATE | AJINOMOTO CO., INC., (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-2653498-B1 | POLYBUTYLENE TEREPHTHALATE RESIN COMPOSITION AND PELLET THEREOF | WINTECH POLYMER LTD (JP) | 2019-01-30 | — | — | EP | disclosed |
| EP-1264844-A1 | MODIFIED BDNF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-20020010215-A1 | Clear aqueous ceramide composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-1153595-A2 | Clear aqueous ceramide composition | Takasago International Corporation (JP) | 2001-11-14 | — | — | EP | disclosed |
| WO-1999010359-A2 | LIPOSOMIC BASED SIALYL LEWIS X MIMETICS | NOVARTIS AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998018805-A2 | SUGAR DERIVATIVES AS SIALYL LEWIS X MIMETICS | NOVARTIS AG (CH) | 1998-05-07 | — | — | WO | disclosed |
| US-5741816-A | CARNITINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | PLIN5, PHOSPHO1, PLIN3 | TSHR 1575/4885THRB 3096/4885PTPN7 514/4885 |
| US-20070116757-A1 | Methylene Blue Derivatives | ACMSD, SI, HTR2B | TSHR 4306/4885THRB 3056/4885PTPN7 4473/4885 |
| US-20020010215-A1 | Clear aqueous ceramide composition | CERS2, CERT1, SGMS1 | TSHR 4152/4885THRB 4553/4885PTPN7 1850/4885 |
| US-20080044462-A1 | STABILIZED TRANSDERMAL BUPROPION PREPARATIONS | BDNF, FFAR4, FFAR2 | TSHR 1885/4885THRB 1535/4885PTPN7 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.